Q BioMed is Moving Towards Clinical Trials for Autistic Spectrum Disorder Drug Program

Q BioMed Inc. (OTCQB:QBIO) was featured in an article by R&D regarding their patent-pending QBM001 Autistic Spectrum Disorder (ASD) drug program that is being developed for nonverbal or minimally verbal autistic children. Over the past nine months, the company has been visiting numerous potential trial sites in the US and Europe as they get ready to commence clinical trials on their candidate formulations that provided an improved safety profile in preclinical trials.

In addition to the drug program, Q BioMed has been evaluating diagnostic options that could offer a diagnosis in children as early as two years of age. Currently, there is no diagnostic tool available to doctors to identify the risk of nonverbal or minimally verbal sub group of ASD. The tools that Q BioMed has been evaluating will also be used in the company’s upcoming clinical trial to validate them as potential biomarkers.

The article also mentioned that Q BioMed will be announcing partnerships in the coming months as the required regulatory filings and an IND are submitted prior to the commencement of clinical trials. The company is also in the process of forming partnerships with a contract and development manufacturing organization (CDMO) in order to start manufacturing and contract research organizations (CROs) to finish their preclinical trials.

To view the full article, click here.

Click here to connect with Q BioMed Inc. (OTCQB:QBIO) for an Investor Presentation. 

Source: www.rdmag.com